You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 金斯瑞生物科技漲6% 截至9月末CARVYKTI季度貿易銷售淨額5500萬美元
格隆匯 10-19 09:58
格隆匯10月19日丨金斯瑞生物科技(1548.HK)漲5.85%,報19.18港元,總市值406億港元。金斯瑞生物科技公吿,CARVYKTI™截至9月30日止季度貿易銷售淨額5500萬美元。CARVYKTI(西達基奧侖賽,英文通用名ciltacabtagene autoleucel,簡稱cilta-cel)是一種靶向B細胞成熟抗原(BCMA)的嵌合抗原受體T細胞(CAR-T)療法。此前日本厚生勞動省已批准CARVYKTI用於治療復發或難治性多發性骨髓瘤(RRMM)成人患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account